Full text is available at the source.
Abstract
Partial cellular reprogramming is set to enter a first in-human trial in 2026 for optic neuropathy and glaucoma.
- Partial cellular reprogramming uses Yamanaka factors to revert aging cells to a younger state while maintaining their original function.
- This approach has evolved over more than twenty years from laboratory research to clinical application.
- The intersection of partial cellular reprogramming and plastic surgery may lead to innovative applications in treating age-related conditions.
Simplified